Ref: YCLNEX 2018 9

Title: Growth Factors Profile in Conditioned Medium human Adipose Tissue-derived

Mesenchymal Stem Cells (CM-hATMSCs) Journal: Clinical Nutrition Experimental

Dear Dr. Widowati,

Thank you for submitting your manuscript to Clinical Nutrition Experimental. I have completed the review of your manuscript and a summary is appended below. The reviewers recommend reconsideration of your paper following major revision. I invite you to resubmit your manuscript after addressing all reviewer comments. You may also submit it as a short communication.

When resubmitting your manuscript, please carefully consider all issues mentioned in the reviewers' comments, outline every change made point by point, and provide suitable rebuttals for any comments not addressed.

To submit your revised manuscript:

- Log into EVISE® at: http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR="yclnex">http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR="yclnex">yclnex
- Locate your manuscript under the header 'My Submissions that need Revisions' on your 'My Author Tasks' view
- Click on 'Agree to Revise'
- Make the required edits
- Click on 'Complete Submission' to approve

What happens next?

After you approve your submission preview you will receive a notification that the submission is complete. To track the status of your paper throughout the editorial process, log in to Evise® at:

 $\underline{\text{http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR=YCLN}\\ EX.$

Enrich your article to present your research with maximum impact. This journal supports the following Content Innovations:

- <u>Interactive Plots</u>: Interactive plot viewer providing easy access to the data behind plots. Please prepare a <u>.CSV</u> file with your plot data and test it online <u>here</u> before submitting as supplementary material.
- <u>Interactive MATLAB viewer</u>: Application displaying interactive <u>MATLAB</u> figures. Please prepare a MATLAB <u>.FIG</u> file and test it <u>here</u> before submitting as supplementary material.
- Open Data: Facility to enable authors to share their raw research data under open access CC-BY license. Please upload your raw research data as supplementary

material in any format, selecting the option "Raw research data" when uploading your files.

I look forward to receiving your revised manuscript as soon as possible.

Kind regards,

Professor Singer Editor-in-Chief Clinical Nutrition Experimental

Comments from the editors and reviewers:

-Reviewer 1

_

The authors investigate the growth factor profile in CM-hATMSCs and concludes that FGF is the most important modulator released. This preliminary study is of potential interest in the field of regenerative medicine, however this reviewer has some concerns regarding the publication of the manuscript.

English language must be thoroughly revised throughout the paper, as several passages are difficult to understand in the present form.

Sample were collected from only 3 donors and therefore the study appears very prelimnary and should be reinforced to meet adequate statistical power. Also, n=3, does not allow for data to be presented ad mean±sd, nor for an appropriate use of ANOVA, post-hoc tests or t-tests. Dots for single measurements should be used in graphs.

Data presentation is not appropriate. Figure 1 and 2 are unnecessary and duplicate data presented in figure 3. Instead the authors could show the difference in growth factor secretion between FFP and non FFP treatment.

The discussion section is more an introduction to the role of the measured growth factor than a discussion of obtained results.

Importantly, as FGF shows the higher concentrations, the authors conclude it is the main effector in CM-related regenerative effects and that it could be used in anti-aging products. This conclusion is unsupported by any experimental evidence. Moreover, FGF levels are high also in non FFP treated samples. Importantly, how can the authors state that higher absolute concentrations of any molecule are related to its prominent biological role and to higher effects compared to other factors? Authors should completely revise their conclusions.

-Reviewer 2

-

Noverina and Colleagues report on growth factors in conditioned medium from adipose tissue-derived stem cells with or without treatment with frozen plasma. They observe that fibroblast growth factor is the highest component from the medium under both treatment

conditions. The authors then conclude that FGF as derived from adipose tissue stem cell conditioned medium has potential for wound healing and cell regeneration and that it can be used in anti-aging products. Although the research question is potentially interesting, several relevant concerns need to be addressed:

- 1) Since Figure 1 and 2 are recapitulated in Figure 3, the amount of information reported is limited. This should be reorganized and submitted as a short-communication or a letter with shortening of all sections, unless the authors may provide additional experiments investigating additional regulatory incubation conditions from more subjects.
- 2) The conclusion that FGF has potential for wound healing and cell regeneration, or that it can be used in anti-aging products, cannot be inferred by the current very limited experiments.
- 3) Some additional characteristics of human cell donors should be provided.
- 4) Language revision is needed.

Ref: YCLNEX_2018_9_R1

Title: Growth Factors Profile in Conditioned Medium human Adipose Tissue-derived

Mesenchymal Stem Cells (CM-hATMSCs) Journal: Clinical Nutrition Experimental

Dear Dr. Widowati,

Thank you for submitting your manuscript to Clinical Nutrition Experimental. I have completed the review of your manuscript and a summary is appended below. The reviewers recommend reconsideration of your paper following major revision. I invite you to resubmit your manuscript after addressing all reviewer comments.

When resubmitting your manuscript, please carefully consider all issues mentioned in the reviewers' comments, outline every change made point by point, and provide suitable rebuttals for any comments not addressed.

To submit your revised manuscript:

- Log into EVISE® at: http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR=YCLNEX
- Locate your manuscript under the header 'My Submissions that need Revisions' on your 'My Author Tasks' view
- Click on 'Agree to Revise'
- Make the required edits
- Click on 'Complete Submission' to approve

What happens next?

After you approve your submission preview you will receive a notification that the submission is complete. To track the status of your paper throughout the editorial process, log in to Evise® at:

http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR=YCLN EX.

Enrich your article to present your research with maximum impact. This journal supports the following Content Innovations:

Open Data: Facility to enable authors to share their raw research data under open access CC-BY license. Please upload your raw research data as supplementary material in any format, selecting the option "Raw research data" when uploading your files.

I look forward to receiving your revised manuscript as soon as possible.

Kind regards,

Professor Singer Editor-in-Chief Clinical Nutrition Experimental

Comments from the editors and reviewers:

-Reviewer 1

- The authors have partially improved the manuscript. However, the study remains preliminary. Data analysis and presentation could still be improved, as parametric statistics is not appropriate. This reviewer must point out that, given the low independent sample number, data and conclusions should at least be declared as preliminary in the discussion and conclusions sections.

-Reviewer 2

_

Some improvements have now been achieved following previous recommendations. Given the structure of experiments, I would recommend that the authors explicitly state in the title, discussion and conclusion that this is a preliminary or pilot experiment.

Have questions or need assistance?

For further assistance, please visit our <u>Customer Support</u> site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

Copyright © 2018 Elsevier B.V. | Privacy Policy

Elsevier B.V., Radarweg 29, 1043 NX Amsterdam, The Netherlands, Reg. No. 33156677.

This message was sent automatically. Please do not reply.

Ref: YCLNEX_2018_9_R1

Title: Growth Factors Profile in Conditioned Medium human Adipose Tissue-derived

Mesenchymal Stem Cells (CM-hATMSCs) Journal: Clinical Nutrition Experimental

Dear Dr. Widowati,

Thank you for submitting your revised manuscript for consideration for publication in Clinical Nutrition Experimental. Your revision was received in good order.

To track the status of your manuscript, please log into EVISE® http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR=YCLNEX and locate the submission under the header 'My Submissions with Journal' on your 'My Author Tasks' view.

We appreciate your submitting your revision to this journal.

Kind regards,

Clinical Nutrition Experimental

Have questions or need assistance?

For further assistance, please visit our <u>Customer Support</u> site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

Copyright © 2018 Elsevier B.V. | Privacy Policy

This message was sent automatically. Please do not reply.

Reference: YCLNEX_2018_9_R1

Title: Growth Factors Profile in Conditioned Medium human Adipose Tissue-derived

Mesenchymal Stem Cells (CM-hATMSCs) Journal: Clinical Nutrition Experimental

Dear Dr. Widowati,

I am currently identifying and contacting reviewers who are acknowledged experts in the field. Since peer review is a voluntary service it can take time to find reviewers who are both qualified and available. While reviewers are being contacted, the status of your manuscript will appear in EVISE® as 'Reviewer Invited'.

Once a reviewer agrees to review your manuscript, the status will change to 'Under Review'. When I have received the required number of expert reviews, the status will change to 'Ready for Decision' while I evaluate the reviews before making a decision on your manuscript.

To track the status of your manuscript, please log into EVISE® and go to 'My Submissions' via:

Kind regards,

Clinical Nutrition Experimental

Have questions or need assistance?

For further assistance, please visit our <u>Customer Support</u> site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

Copyright © 2018 Elsevier B.V. | Privacy Policy

Elsevier B.V., Radarweg 29, 1043 NX Amsterdam, The Netherlands, Reg. No. 33156677.

RESPOND TO REVIEWERS

On Article entitled "Growth Factors Profile in Conditioned Medium human Adipose

Tissue-derived Mesenchymal Stem Cells (CM-hATMSCs)"

Reviewer 1

1. The authors investigate the growth factor profile in CM-hATMSCs and concludes that FGF is the most important modulator released. This preliminary study is of potential interest in the field of regenerative medicine, however this reviewer has some concerns regarding the publication of the manuscript.

English language must be thoroughly revised throughout the paper, as several passages are difficult to understand in the present form.

Respond:

Thank your for your comment, we have corrected the the english writings as suggested

2. Sample were collected from only 3 donors and therefore the study appears very prelimnary and should be reinforced to meet adequate statistical power. Also, n=3, does not allow for data to be presented ad mean±sd, nor for an appropriate use of ANOVA, post-hoc tests or t-tests. Dots for single measurements should be used in graphs.

Respond:

Thank you for your comment on our article. We only used 3 donors however we conducted this study with many treatments such as treatment with FFP and non FFP also treatment in many passages, but we only use passage 3, 7, 11 and 15 as they have significant different among others.

3. Data presentation is not appropriate. Figure 1 and 2 are unnecessary and duplicate data presented in figure 3. Instead the authors could show the difference in growth factor secretion between FFP and non FFP treatment.

Respond:

Thank you for your comment. We have corrected the figures as you suggested.

4. The discussion section is more an introduction to the role of the measured growth factor than a discussion of obtained results.

Respond:

Thank you for your comment. We have corrected the the discussion as you suggested

5. Importantly, as FGF shows the higher concentrations, the authors conclude it is the main effector in CM-related regenerative effects and that it could be used in anti-aging products. This conclusion is unsupported by any experimental evidence. Moreover, FGF levels are high also in non FFP treated samples. Importantly, how can the authors state that higher absolute concentrations of any molecule are related to its prominent biological role and to higher effects compared to other factors? Authors should completely revise their conclusions.

Respond:

Thank you for your comment. We have corrected the conclusion as you suggested

Reviewer 2

Noverina and Colleagues report on growth factors in conditioned medium from adipose tissue-derived stem cells with or without treatment with frozen plasma. They observe that fibroblast growth factor is the highest component from the medium under both treatment conditions. The authors then conclude that FGF as derived from adipose tissue stem cell conditioned medium has potential for wound healing and cell regeneration and that it can be used in anti-aging products. Although the research question is potentially interesting, several relevant concerns need to be addressed:

1) Since Figure 1 and 2 are recapitulated in Figure 3, the amount of information reported is limited. This should be reorganized and submitted as a short-communication or a letter with shortening of all sections, unless the authors may provide additional experiments investigating additional regulatory incubation conditions from more subjects.

Respond:

Thank you for your comment. We have corrected the figure as you suggested. As for our study we used many treatment such as treatment with FFP and non FFP also treatment in many passages, but we only use passage 3, 7, 11 and 15 as they have significant different among others, and so we thought that our data was enough.

2) The conclusion that FGF has potential for wound healing and cell regeneration, or that it can be used in anti-aging products, cannot be inferred by the current very limited experiments.

Respond:

Thank you for your comment. We have corrected the conclusion as you suggested.

3) Some additional characteristics of human cell donors should be provided.

Respond:

Thank you for your comment. We have added characteristics of human cell donors in introduction section.

4) Language revision is needed.

Respond:

Thank you for your comment. We have revised our english writing based on suggestion.

Our reference: YCLNEX 86 P-authorquery-v9

AUTHOR QUERY FORM



Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. It is crucial that you NOT make direct edits to the PDF using the editing tools as doing so could lead us to overlook your desired changes. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

Location in article	Query / Remark: Click on the Q link to find the query's location in text Please insert your reply or correction at the corresponding line in the proof	
Q1	Please check whether the order of the designated corresponding authors are correct, and amend if necessary.	
Q2	Please check the address for the corresponding author that has been added here, and correct if necessary.	
Q3	Have we correctly interpreted the following funding source(s) and country names you cited in your article Ministry of Research, Technology and Higher Education of the Republic of Indonesia, Indonesia?	
Q4	Please note that as per the journal style, if there are more than 6 authors/editors, the first 6 author names are listed followed by 'et al' if the author group consists of 6 authors or fewer, all author names should be listed. Therefore, in Ref(s). [14]; [26]; please list all names for up to 6 authors/editors. For more than 6 authors/editors, use 'et al' after the first 6 authors/editors.	
Q5	Uncited references: This section comprises references that occur in the reference list but not in the body the text. Please position each reference in the text or, alternatively, delete it. Any reference not dealt wi will be retained in this section. Thank you.	
Q6	Please confirm that given names and surnames have been identified correctly and are presented in the desired order and please carefully verify the spelling of all authors' names.	

	Please check this box or indicate your approval if you have no corrections to make to the PDF file	
--	--	--

Thank you for your assistance.